Clinical Research Details
Title:
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Purpose:
The purpose of this study is to determine patient outcomes following high dose combination chemotherapy treatment and to compare higher dose vincristine with compared to standard dose vincristine
Study Number:
200749041608
Number of Patients:
10
Elgibility:
Patients with an initial intermediate-risk relapse of B-precursor ALL Intermediate-risk relapse is defined as: Bone marrow relapse = 36 months from initial diagnosis, or combined bone marrow & extramedullary (CNS and/or testicular) relapse = 36 months from initial diagnosis, or isolated extramedullary (CNS and/or testicular) relapse < 18 months from diagnosis.
Treatment:
You will go on one of two different treatment plans. The plan you are assigned to is decided by randomization (chance). The only difference between treatments of the two plans is that participants will receive a different dose of vincristine during some stages of therapy. Some participants will be randomized to receive the standard dose of vincristine during treatment; others will get a higher dose of vincristine. The treatment plan involves cancer-fighting medicine called chemotherapy and may include radiation therapy. Treatment on this clinical trial will take about 27 months (a little over two years). It is divided into seven stages: Induction 1; Induction 2; Induction 3; Intensification 1; Re-induction; Intensification 2 and Maintenance. After the Induction 3 phase of treatment, participants who have a matched family member who is a suitable donor for bone marrow transplant will be recommended to have a bone marrow transplant rather than receive the rest of the chemotherapy treatment.
Principal Investigator:
Enrollment Phone:
(708) 216-2026